Cornell research team to develop COVID-19 nose spray treatment. These agents essentially trick the virus by changing the structure of the outside of cells, so they look like a virus has already fused to them. Boots Dual Defence Nasal Spray 20ml - Boots The reduction in the symptom score was clinically relevant for all three groups. Bearing in mind that viral load might be a surrogate measure of infectiousness, those results are encouraging as they indicate that azelastine may be a promising candidate for preventing the spread of this disease. Although no significant differences between groups regarding the total symptom score was shown, it may be speculated that the 0.1% azelastine spray may have positive influences on single symptoms such as shortness of breath, which was improved significantly greater in this treatment group compared to placebo at early time points of infection. Science 371, 13791382 (2021). https://doi.org/10.1007/s11739-021-02786-w (2021). https://doi.org/10.7554/eLife.69302 (2021). 31(6), 113. Since the start of the Coronavirus Disease 2019 (COVID-19) pandemic, several independent research groups revealed azelastines potential as a promising candidate for drug repurposing to reduce SARS-CoV-2 viral load and infection rates5,6,7,8,9,10. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. ICE-COVID, will investigate whether Dual Defence can either prevent Covid-19 infection or reduce . 24 COVID-19 status classified as negative, asymptomatic, mild, or severe. If all goes well, the hope is that we'll have a safe and effective nasal spray to serve as an extra line of defense in the fight against COVID-19. What scientists say. The study was termed CARVIN (referring to COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs). 8, 701709. Odhar, H. A. et al. The dual-target RT-PCR independently targets the ORF1a/b and the sarbecovirus E genes, and assays were considered positive if at least one target returned a positive result (Ct values reflecting an inverse relationship with viral load). Lee, K. (2022, April 27). Carrageenan Nasal Spray for COVID-19 Prophylaxis (ICE-COVID) Topol is also editor-in-chief of Medscape, WebMD's sister site for medical professionals. Early intervention with azelastine nasal spray may reduce viral load in When treated with N-0385, 70% of the mice survived and had little to no lung damage. A closer look at single symptoms confirmed moderate expression of symptoms (supplementary Figure S1) and the general decrease of symptoms over time (supplementary Figure S2). Quality of life was assessed with the SF-36 questionnaire as no COVID-19 specific patient-reported outcome measures were available at the time of study. https://doi.org/10.1080/14787210.2021.1908127 (2021). Article Sci Rep 13, 6839 (2023). Patients were assigned a treatment number in an ascending mode according to their chronological order of inclusion. Scientists are working on fast-acting nasal sprays to block coronavirus infections but formulating the sprays is a challenge. Allergy Asthma Immunol. The aim of our study was to support the preclinical evidence for azelastines antiviral activity in patients tested positive for SARS-CoV-2. Dis. In addition, presence or absence of fever (38.0C) was documented daily (0=no fever, 3=fever). Patient Rep. Outcomes 6, 26. https://doi.org/10.1186/s41687-022-00434-1 (2022). Could a Nasal Spray of Designer Antibodies Help to Beat COVID-19? Upon treatment, a gradual decline of viral load from baseline (day 1) to day 11 of treatment was observed in all three study groups. Boots Dual Defence, which contains Carragelose, a patented version of iota-carrageenan, is already clinically proven to help shorten the duration and severity of cold and flu-like symptoms,[ii] and new in-vitro (test tube) laboratory study results suggest that Carragelose could also reduce the risk of an infection with SARS-CoV-2, the virus which Carrouel, F. et al. https://cornellsun.com/2022/04/27/cornell-research-team-to-develop-covid-19-nose-spray-treatment/, Shapira, T., Monreal, I. Future studies will help understanding the impact of azelastine hydrochloride in treating SARS-CoV-2 infected patients. E.N., V.S., G.N., R.K., A.B., M.F. Asthma Allergy Immunol. Nature 605, 340348 (2022). Studies into Xlear's antiviral effects on SARS . J. https://doi.org/10.1007/s10787-021-00847-2 (2021). 03:08. PubMed Central Our study results provide the first human data showing that azelastine hydrochloride nasal spray used in a 0.1% concentration may be effective in accelerating the reduction of virus load in the nasal cavity and improving symptoms reported by COVID-19 patients. March 31, 2023 - An antiviral therapy in early development has the potential to prevent COVID-19 infections when given as a nasal spray as little as 4 hours before exposure. Pharmacol. Boots Dual Defence Nasal Spray Bundle 4X 20ml - Boots It should be noted that the SARS-CoV-2 alpha variant (B.1.1.7) was the dominant variant in Germany during the enrolment phase of the current study16. Short intervals of swab collection time points, particularly during early days of infection, and high number of PCR tests aimed to monitor SARS-CoV-2 viral loads as closely as possible, considering that only limited knowledge regarding details of viral clearance was publicly available at the time of the study development. Z. Gesundheitswissenschaften J. https://doi.org/10.1016/s1081-1206(10)63465-5 (1996). BR, SMS, HS, CA, NW, SA, and RM are employees of ClinCompetence Cologne, the CRO which organized this trial. SARS-CoV-2 infection progression starts with viral entrance mediated by the spike glycoproteins interaction with the host ACE2 receptor molecule. Recently, Shmuel et al. The spritz developed by Moscona's team is one of a raft of proposed nasal sprays to prevent SARS-CoV-2 infection. It also appears to . Prevention is the best medicine, and COVID-19 vaccines block most SARS-CoV-2 infections. PubMed PubMed At V1, a comparable distribution of patients with a score of 1 (14.8% in the 0.1% azelastine group, 14.3% in the 0.02% azelastine group and 23.1% in the placebo group) or 2 (85.2% in the 0.1% azelastine group, 85.7% in the 0.02% azelastine group and 76.9% in the placebo group) was observed. Emerg. The researchers compared mice treated with TriSb92 before and after exposure to SARS-CoV-2. Samples were processed on the day of receipt at the central processing laboratory (Institute of Virology, University Hospital Cologne, Cologne, Germany) by vortexing and aliquoting the viral transport medium and stored at80C until analysis. To obtain PDF Effect of nasal carriage of Bacillus species on COVID-19 severity: A Could a nose spray a day keep COVID away? - nature.com Boots cold and flu nasal spray that costs just 6 could stop - The Sun Simon, M. W. The efficacy of azelastine in the prophylaxis of acute upper respiratory tract infections. How nasal-spray vaccines could change the pandemic, How much virus does a person with COVID exhale? and B.S. CAS 384, 671673. Evaluation of AUC values (reflecting baseline adjusted decreases of viral load over 11days) showed that the 0.1% azelastine group exhibited a greater AUC value of 24.1413.12 (referring to greater decrease) compared to the placebo group with an AUC value of 18.894.70 (p=0.007, Fig. PubMedGoogle Scholar. When the treatment course was shortened to four days, starting one day before infection, all 10 of the mice treated with N-0385 survived. Xlear have developed and patented a xylitol containing nasal spray for the treatment of upper-respiratory tract infections. Head Neck Surg. The Coronavirus Immunotherapy Consortium identified new candidate drugs based on monoclonal antibodies in work funded by NIAID. Identification of antiviral antihistamines for COVID-19 repurposing. Article Slider with three articles shown per slide. Marshall, J. C. A minimal common outcome measure set for COVID-19 clinical research. https://doi.org/10.1021/acsmedchemlett.0c00521 (2020). Anyone you share the following link with will be able to read this content: Sorry, a shareable link is not currently available for this article. Comirnaty may help your body develop immunity to SARS-CoV-2, the virus that causes COVID-19. Of note, we cannot rule out the possibility that the placebo (nasal spray buffer) contributed to viral clearance. During the treatment phase, 7 visits (V1V7) took place on days 1, 2, 3, 4, 5, 8 and 11. Data was analysed primarily exploratively; there was no formal testing of a given hypothesis. We are aware that this limited the capture of COVID-19 specific issues as questions were not specifically aimed for COVID-19 patients. Ghahremanpour, M. M. et al. Both descriptive and exploratory statistics were performed. Ann. Commun. C.L. The current study was a randomized, parallel, double-blind, placebo-controlled trial. https://doi.org/10.6026/97320630016236 (2020). Res. Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19, Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19, Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease, Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19, Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial, Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom, Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity, Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates, Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2, https://doi.org/10.1038/s41591-022-01780-9, https://doi.org/10.1016/s1081-1206(10)63465-5, https://doi.org/10.1038/s41401-020-00556-6, https://doi.org/10.1016/j.bbrc.2020.11.095, https://doi.org/10.1021/acsmedchemlett.0c00521, https://doi.org/10.1007/s11224-020-01605-w, https://doi.org/10.3389/fphar.2022.861295, https://doi.org/10.1016/s1473-3099(20)30483-7, https://doi.org/10.1007/s11739-021-02786-w, https://doi.org/10.1016/s2213-2600(20)30354-4, https://doi.org/10.21203/rs.3.rs-864566/v1, https://doi.org/10.1038/s41598-021-04573-1, https://doi.org/10.1007/s43440-023-00463-7, https://doi.org/10.1016/j.jinf.2021.05.009, https://doi.org/10.1080/14787210.2021.1908127, https://doi.org/10.3390/pharmaceutics14112502, https://doi.org/10.1001/jamaoto.2020.5490, https://doi.org/10.1007/s10787-021-00847-2, https://doi.org/10.1038/s41591-021-01316-7, https://doi.org/10.1038/s41586-020-2196-x, https://doi.org/10.1186/s12985-021-01559-3, https://doi.org/10.1089/088318703322751327, https://doi.org/10.1186/s41687-022-00434-1, https://doi.org/10.1038/s41586-021-04388-0, https://doi.org/10.3390/pharmaceutics14102059, http://creativecommons.org/licenses/by/4.0/, Cancel Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail is a medical device innovated to provide the dual-action physical barrier on nasal mucosa that aids the natural defence in which the mucus layer is fortified by a steric barrier-forming agent HPMC and invading viral particles of all major SARS-CoV-2 It would be desirable to use a validated, COVID-19 specific questionnaire in future studies, and first attempts for its development are promising32. Front. Bioinformation 16, 236244. Reznikov, L. R. et al. Of note, the mean viral load value showed small variability, thereby supporting the power of the current study. Overall, the current results are encouraging; however, further studies should be carried out to strengthen the findings, and treatment should be extended to other age and risk groups and cover individuals with different levels of symptom severity. Vitiello, A., Ferrara, F., Troiano, V. & La Porta, R. COVID-19 vaccines and decreased transmission of SARS-CoV-2. Chem. Whether the current data can be extrapolated to other SARS-CoV-2 variants needs to be investigated. Ctcycle threshold. were investigators involved in the conduct of the study. Biochem. Our study population was characterized by an initial mean viral load of log10 6.851.31cp/mL, which was higher than more recently reported SARS-CoV-2 viral load values26. The researchers picked four compounds that worked at very low concentrations and did not negatively affect the host cells. Performance of self-collected saliva testing compared with nasopharyngeal swab testing for the detection of SARS-CoV-2. When treated with N-0385, 70% of the mice survived and had little to no lung damage. A research study at Swansea University is examining the efficacy of Boots Dual Defence - a 5.99 nasal spray containing seaweed - in preventing people becoming ill with Covid and reducing the . If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. B.R. Xylitol Based Nasal Spray for COVID-19 Treatment J.P.K. Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. 59.3% (0.1% azelastine treatment), 50.0% (0.02% azelastine treatment) and 80.8% (placebo treatment) of patients assessed the overall tolerability of the treatment as very good, which mirrored the tolerability judgement of the investigators, which was assessed as very good for 59.3% (0.1% azelastine treatment), 50.0% (0.02% azelastine treatment) and 80.8% (placebo treatment) of patients. Smell retraining therapy (SRT) is a treatment for loss of smell, also referred to as hyposmia or anosmia. One of these smaller antibodies is being developedfrom llamas for example; another comes fromexperiments with yeast to develop synthetic nanobodies; and in a third case, researchers isolated nanobodiesfrom llamas and from mice and showed they could neutralize the SARS-CoV-2 virus. Comirnaty is also authorized . Other evidence of viral infection showed similar differences between treated and untreated mice in the protective lining of cells called the, inside the nose, nasal mucosa, and airways., : Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants.. When the treatment course was shortened to four days, starting one day before infection, all 10 of the mice treated with N-0385. PubMed Central You can also search for this author in PubMed As expected, a continuous decrease in the mean virus load was observed in all study groups during the 11 treatment days. Med. Jean, F. (2022). Analyses were done on the entire data set (ITT) as well as on a subset population with high viral load defined by baseline Ct values below 25 (Ct<25). By blocking that access, compounds that target TMPRSS2 have the potential to be effective against both current and future variants. At the end of the treatment, 48.2% of the patients of the 0.1% azelastine group showed no detection of the ORF 1a/b gene, whereas only 23.1% of patients of the placebo group showed negative PCR results (supplementary Table S4). For calibration purposes of quantitative assessments, reference samples were included with each PCR run. Suitable for Shmuel, K., Dalia, M., Tair, L. & Yaakov, N. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: An observational prospective open label user survey. Article the epithelium, to recreate the first line of defense against respiratory viruses. In addition, patient's quality of life was evaluated by the SF-36 questionnaire, covering 36 items divided into the 8 quality of life domains physical functioning; role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health12. Wiesmller (health authorities Cologne, Germany) for his support regarding regulatory issues, PD Dr. E. Raskopf for editorial assistance, and H. Papp for her assistance in PCR control experiments. It would be desirable to extend the investigation of azelastine nasal spray as potential antiviral treatment with in vitro culture experiments. New methods of fast-acting COVID-19 prevention are being researched to make it safer to be in large public gatherings like sporting events or concerts. Postdoctoral Associate- Immunology, T Cells, GVHD, Bone Marrow Transplantation, Postdoctoral Fellows in the VU Department of Biochemistry. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. The Sponsor designed a dual chamber nasal spray bottle for NORS administration. the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in It's being studied as a potential way to prevent mild to moderate cases of COVID-19. Assignment of the treatment with the investigational medicinal product in the different doses vs. placebo to each treatment number was performed in a centrally conducted, computer-generated 1:1:1 randomization procedure.